Kisqali 200 mg Tablets (Ribociclib) – Targeted Cancer Therapy

About Kisqali 200 mg Tablets

Kisqali (ribociclib) 200 mg is an advanced targeted therapy indicated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.

How Kisqali Works

As a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, Kisqali works by blocking specific proteins in cancer cells that promote their growth and division. By inhibiting these enzymes, it helps to slow the progression of the disease.

Important Usage Information

• Administration: Kisqali is for oral administration only.
• Dosage: Each carton contains 21 film-coated tablets (comprimidos recubiertos con pelicula).
• Professional Oversight: This is a highly specialized oncological medication that must be prescribed and monitored by an oncologist.
• Safety: Always store in a controlled environment according to the package insert provided by Novartis.

Patients should strictly follow the dosing schedule provided by their physician and read the medication guide thoroughly before initiating therapy.